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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of death and dis-
ability internationally. Alveolar hypoxia and consequent hypoxemia increase in prevalence as 
disease severity increases. Ventilation/perfusion mismatch resulting from progressive airflow 
limitation and emphysema is the key driver of this hypoxia, which may be exacerbated by sleep 
and exercise. Uncorrected chronic hypoxemia is associated with the development of adverse 
sequelae of COPD, including pulmonary hypertension, secondary polycythemia, systemic inflam-
mation, and skeletal muscle dysfunction. A combination of these factors leads to diminished 
quality of life, reduced exercise tolerance, increased risk of cardiovascular morbidity, and greater 
risk of death. Concomitant sleep-disordered breathing may place a small but significant subset 
of COPD patients at increased risk of these complications. Long-term oxygen therapy has been 
shown to improve pulmonary hemodynamics, reduce erythrocytosis, and improve survival in 
selected patients with severe hypoxemic respiratory failure. However, the optimal treatment 
for patients with exertional oxyhemoglobin desaturation, isolated nocturnal hypoxemia, or 
mild-to-moderate resting daytime hypoxemia remains uncertain.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity 
and disability, and by 2020 is predicted to become the third greatest cause of death 
worldwide.1 As pulmonary function deteriorates, and as the disease progresses, the 
risk of alveolar hypoxia and consequent hypoxemia increases.2 A mounting body of 
evidence suggests that hypoxemia is more than a signifier of advanced disease. Rather, 
it now seems clear that tissue hypoxia is a key player in many of the maladaptive 
processes and extrapulmonary comorbidities that characterize COPD.
The prevalence of hypoxemia among COPD patients remains somewhat uncertain. 
In large general COPD populations, severe hypoxemia is relatively uncommon, with 
only 2% of the 5993 participants in the UPLIFT® trial being prescribed supplemental 
oxygen.3 Conversely, over 80% of the patients with advanced disease enrolled in the 
National Emphysema Treatment Trial were using some form of oxygen therapy.4
Hypoxemia associated with COPD contributes to reduced quality of life, diminished 
exercise tolerance, reduced skeletal muscle function, and ultimately increased risk 
of death.5 On the other hand, treatment of severe hypoxemia with long-term oxygen 
therapy (LTOT) is one of the few interventions shown to prolong life in hypoxemic 
COPD patients.5 This review will examine how alveolar hypoxia and hypoxemia arise 
in COPD patients, the adverse consequences of chronic hypoxemia in COPD patients, International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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and some of the benefits and drawbacks of supplemental 
oxygen therapy in COPD.
Pathophysiology of alveolar hypoxia 
and hypoxemia in COPD
The principal contributor to hypoxemia in COPD patients 
is ventilation/perfusion (V/Q) mismatch resulting from 
progressive airflow limitation and emphysematous destruc-
tion of the pulmonary capillary bed.6 In studies utilizing the 
multiple inert gas elimination technique, COPD patients 
with a predominantly emphysematous phenotype have 
increased ventilation of poorly perfused lung units (ie, high 
V/Q ratio), and hence increased physiological dead space.7 
Conversely, subjects with a significant degree of airway 
disease are more likely to have a low V/Q ratio, with het-
erogeneous alveolar hypoventilation, substantial perfusion 
of under-ventilated areas, and consequent physiological 
shunt. V/Q mismatch due to pulmonary emphysema and 
small airways disease is measurable even in subjects 
with mild COPD,8 but appears to increase with disease 
progression.9
Exacerbations of COPD are frequently associated with 
deterioration in gas exchange and associated hypoxemia. 
Unsurprisingly, increased inequality in V/Q relationships 
appears to be the major determinant of these changes.10 
Increased tissue consumption of oxygen, with resultant 
decreased mixed venous oxygen tension also appears to 
contribute to increased hypoxemia during exacerbations, 
but is at least partially offset by a concomitant increase in 
cardiac output.
Obesity is increasingly prevalent in modern COPD 
cohorts, and may contribute to abnormalities in gas 
exchange.11 Even in the absence of COPD, obesity is associ-
ated with small airways dysfunction, decreased chest wall 
compliance, V/Q mismatch, and increased peripheral oxygen 
consumption, all potentially leading to relative hypoxemia. 
Risk of sleep-disordered breathing and consequent nocturnal 
hypoxemia correlates with the degree of obesity,12 and in 
extreme cases, morbid obesity can lead to profound alveo-
lar hypoventilation, with chronic hypercapnic respiratory 
failure.13
Dysregulated ventilatory control is another factor con-
tributing to the occurrence and persistence of hypoxemia in 
COPD patients. Subjects with chronic airflow obstruction 
have blunted ventilatory responses to hypoxia,14 and this 
is particularly the case in those with chronic hypoxemia.15 
In the majority of cases, this is not driven by diminished 
central nervous system output, with COPD patients often 
exhibiting increased neural drive to the respiratory muscles 
as the disease progresses.16 Rather, peripheral mechanisms 
related to disordered inspiratory muscle function and asso-
ciated hyperinflation appear to be the key.6 Nonetheless, 
reduction in central ventilatory drive may be of relevance 
in cases of nocturnal hypoxemia, in bronchial type (“blue 
bloater”) patients, and with use of sedatives, hypnotics, 
and alcohol.
Exercise, COPD, and hypoxemia
Exercise may actually improve gas exchange in subjects with 
mild COPD, largely due to an improvement in V/Q relation-
ships resulting from more even distribution of ventilation.17 
However, in more severe disease, V/Q mismatching and 
peripheral oxygen extraction are increased,18 and dynamic 
hyperinflation contributes to alveolar hypoventilation,19 with 
resultant exertional hypoxemia.
Desaturation with exercise appears to predict increased 
risk of mortality,20 but the role of supplemental oxygen in 
this area is uncertain. A number of studies have shown it to 
provide short-term symptom relief and exercise performance, 
but longer-term data are lacking.21 Similarly, there is little 
evidence in the published literature to support a role for 
ambulatory oxygen therapy in prolonging survival. While 
often viewed as an attractive therapeutic option, the use of 
supplemental oxygen is not free of risk or adverse conse-
quences, and this will be discussed in greater detail later in 
this review. The ongoing Long-term Oxygen Treatment Trial 
is a large-scale, multicenter attempt to address knowledge 
deficits in this field.21
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Figure 1 Hypoxia-related factors contributing to the development of pulmonary 
hypertension in chronic obstructive pulmonary disease.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Sleep, COPD, and hypoxemia
Sleep has significant effects on respiration, even in healthy 
subjects. Chemoreceptor sensitivity decreases,   respiratory 
motor output, and muscle contraction diminish,   ventilation/
perfusion relationships alter, and airflow resistance 
increases. The net effect of these changes is relative alveo-
lar hypoventilation, which is particularly pronounced in 
rapid-eye-movement sleep. While clinically unimportant 
in otherwise healthy individuals, these changes can lead to 
significant nocturnal hypoxemia in patients with COPD.22
While diaphragmatic function is maintained during rapid-
eye-movement sleep, contraction of the accessory muscles 
is markedly reduced. In the presence of pulmonary hyper-
inflation and consequent reduced diaphragmatic efficiency, 
this can lead to pronounced hypoventilation. Furthermore, 
subjects with COPD and mild daytime hypoxemia may be 
particularly vulnerable to oxyhemoglobin desaturation during 
sleep, because they will often reside on the steep portion of 
the oxyhemoglobin dissociation curve.22 Interestingly, COPD 
patients may be relatively protected from the potential det-
rimental effects of rapid-eye-movement sleep, because they 
have reduced sleep quality, with sleep fragmentation and 
consequent reduction in slow-wave and rapid-eye-movement 
sleep duration.23
Respiration during sleep is of particular relevance to 
a subset of COPD patients with coexisting obstructive 
sleep apnea syndrome, the so-called overlap syndrome. 
Community-based population studies would suggest the 
overlap syndrome occurs in at least 1% of adults, with the 
prevalence of obstructive sleep apnea syndrome in COPD 
patients approximating that in the general population.23,24 
Overlap patients have more pronounced nocturnal hypox-
emia, are more likely to develop pulmonary hypertension, 
and appear to be at increased risk of death compared with 
COPD patients matched for Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage.25,26 At a molecular 
level, the systemic inflammation associated with COPD and 
obstructive sleep apnea syndrome may act synergistically to 
promote the development of atherosclerosis and subsequent 
overt cardiovascular disease, although further studies in this 
area are needed.25
A number of interventions may be of benefit in COPD 
patients with significant nocturnal hypoxemia. The available 
evidence does not suggest supplemental oxygen provides a 
survival benefit in COPD patients with isolated nocturnal 
desaturation,27 but its prescription may be appropriate in 
such cases if complicated by pulmonary hypertension or 
polycythemia. Care should be taken to avoid the   development 
of hypercapnia as a result of abolition of hypoxic respiratory 
drive, although the available evidence indicates that 
the degree of elevation in arterial carbon dioxide tension 
during sleep with supplemental oxygen therapy in COPD 
patients is mild and nonprogressive.28 Theophylline acts as 
a central respiratory stimulant and improves diaphragmatic 
contractility, thus improving gas exchange during sleep in 
COPD,29 and has the added benefit of reducing the level 
of sleep-disordered breathing in obstructive sleep apnea 
  syndrome.30 Furthermore, bronchodilatation with long-acting 
anticholinergic agents and long-acting β-agonists may also 
be beneficial.31,32 Meanwhile, administration of nocturnal 
continuous positive airway pressure therapy appears to 
abrogate the increase in mortality seen in patients with the 
overlap syndrome.26
Consequences of hypoxemia  
in COPD
Pulmonary hypertension
Alveolar hypoxia is an important contributory factor to the 
development of pulmonary hypertension in patients with 
COPD.33 The exact prevalence of pulmonary hypertension 
in COPD remains uncertain, but it appears to be relatively 
common in moderate–severe disease,34 and increases in 
prevalence with disease severity. In a series of 120 patients 
with severe emphysema enrolled in the National Emphysema 
Treatment Trial who underwent right heart catheterization, 
90.8% had pulmonary artery pressures above the normal 
range.35 The degree of pulmonary hypertension in this study 
correlated with severity of emphysema as measured by forced 
expiratory volume in one second and diffusion lung capacity 
for carbon monoxide. Similarly, in a population of 215 French 
COPD patients listed for lung transplant or lung volume 
reduction surgery, pulmonary hypertension was present in 
50.2% of cases.36
A striking feature of modern studies, however, is the 
preponderance of mild pulmonary hypertension even 
in severe COPD. Of the patients with advanced disease 
studied in the National Emphysema Treatment Trial, only 
5% had severe pulmonary hypertension (pulmonary artery 
pressure . 35 mmHg).35 Similarly, in a large retrospective 
study of COPD patients undergoing right heart catheter-
ization, only 27 of 998 subjects had a pulmonary artery 
pressure . 40 mmHg.34 Thabut et al identified a small subset 
of “atypical” patients with severe pulmonary hypertension 
and marked hypoxemia, but only moderately severe COPD.36 
Therefore, the discovery of severe pulmonary hypertension in 
COPD patients should lead to investigation for contributory International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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comorbidities, such as obstructive sleep apnea syndrome, 
obesity-hypoventilation syndrome, and chronic thromboem-
bolic disease.
In the majority of cases, COPD-related pulmonary 
hypertension will progress slowly, if at all, although pul-
monary artery pressure can transiently increase during acute 
exacerbations.37 A minority of cases will go on to develop 
the overt right heart failure and peripheral edema that char-
acterize cor pulmonale. The occurrence of cor pulmonale 
portends a significantly worse prognosis for the patient.38 
A potential contributory factor to this is worsening of noc-
turnal hypoxemia, due to rostral shift of peripheral edema 
leading to compromise of the upper airway and associated 
alveolar hypoventilation.39
Factors contributing to the development of   pulmonary 
hypertension at an anatomic level include   emphysematous 
obliteration of the pulmonary capillary bed, thromboem-
bolic disease, and pulmonary vascular constriction and 
  remodeling.40 The pulmonary vasculature of COPD patients 
with pulmonary hypertension is characterized by luminal 
  narrowing due to thickening of the intima, along with 
  arteriolar muscularization. These changes may be observed 
in mild COPD, and even in otherwise healthy smokers, 
suggesting pulmonary vascular changes may arise before 
clinically overt disease.41
At a functional level, a key factor contributing to the 
development of increased pulmonary vascular resistance 
is hypoxic pulmonary vasoconstriction, driven by alveolar 
hypoxia.33 Indeed, the degree of pulmonary vasoconstric-
tion appears contingent on the severity and duration of 
hypoxia.42,43 The molecular basis of this response remains 
uncertain. Hypoxia appears to induce calcium influx with 
consequent membrane depolarization in pulmonary arte-
rial smooth muscle cells, while hypoxia-driven Rho kinase 
activation may also contribute to increased vascular tone.44 
However, mitochondrial and NADPH oxidase function, and 
associated generation of reactive oxygen species, also appear 
to play a key role.45
Hypoxia also appears to contribute to the development of 
endothelial dysfunction, characterized by loss of the physi-
ological balance between vasodilation and vasoconstriction. 
The key mediator of endothelium-dependent vasodilation is 
nitric oxide, the constitutional expression of which is depen-
dent on endothelial nitric oxide synthase activity. Hypoxia 
has been demonstrated to impair endothelium-dependent 
pulmonary artery relaxation in subjects with severe COPD, 
suggesting a diminution of nitric oxide bioavailability.46 
Conversely, hypoxia appears to upregulate production of 
vasoconstrictive mediators, such as endothelin-1, thus leading 
to increased vascular tone.47 Other factors related to hypoxia 
that may contribute to the development of pulmonary hyper-
tension, such as systemic inflammation and polycythemia, 
are discussed in detail elsewhere in this review.
A number of studies have suggested a link between 
defined genetic mutations and the occurrence of pulmonary 
hypertension in COPD. The largest of these is the National 
Emphysema Treatment Trial Genetics Ancillary study, which 
examined candidate gene single nucleotide polymorphisms 
in 389 subjects with severe COPD.48 In this cohort, a single 
nucleotide polymorphism within the surfactant protein-B 
gene was associated with elevated systolic pulmonary artery 
pressure. Meanwhile, separate studies by Eddahibi et al show 
that polymorphisms in the serotonin transporter gene and 
the interleukin-6 gene confer increased risk of pulmonary 
hypertension in COPD patients.49,50 However, conflicting 
results have been reported in studies evaluating the role of 
endothelial nitric oxide synthase and angiotensin-converting 
enzyme polymorphisms.51–53 To date, no large-scale link-
age studies or genome-wide association studies have been 
published in this field.
LTOT is the treatment of choice for COPD patients 
with pulmonary hypertension. Subjects receiving continu-
ous oxygen therapy in the Nocturnal Oxygen Therapy Trial 
showed a reduction in pulmonary vascular resistance and 
pulmonary artery pressures,54 while LTOT led to stabiliza-
tion of pulmonary hemodynamics in the Medical Research 
Council study.55 In contrast, there is little evidence to support 
the use of dedicated pharmacological therapies for pulmonary 
hypertension, including calcium channel blockers, inhibitors 
of the renin-angiotensin system, endothelin-receptor antago-
nists, prostacyclin analogs, or phosphodiesterase-5 inhibitors. 
While some of these interventions may improve pulmonary 
hemodynamics, this has been observed to occur at the expense 
of a deterioration in gas exchange in some patients.56
In the pre-LTOT era, the presence of pulmonary hyper-
tension portended a particularly poor prognosis for COPD 
patients. In 1981, Weitzenblum et al found subjects with a 
mean pulmonary artery pressure of .20 mmHg at   baseline 
had a seven-year survival of 29.2% versus 55.6% in the group 
without pulmonary hypertension.57 Conversely, a   normal 
pulmonary artery pressure was predictive of   prolonged 
  survival.58 Supplemental oxygen therapy appears to 
  stabilize, and occasionally reverse pulmonary hypertension 
in COPD patients.33 Despite this, the presence of pulmonary 
  hypertension remains predictive of adverse outcomes even 
in patients receiving LTOT.59International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Polycythemia
COPD has long been recognized as an important cause of 
secondary polycythemia. Early reports include that of Epstein 
in 1912,60 which described polycythemia occurring in cases 
of “respiratory embarrassment”, including emphysema, 
while an association between the presence of polycythemia 
and increased risk of mortality was observed by Weber in 
1913.61 When present in COPD, polycythemia can contribute 
to the development of pulmonary hypertension, and leads to 
pulmonary endothelial dysfunction, reduced cerebral blood 
flow, hyperuricemia and gout, and increased risk of venous 
thromboembolic disease.62–65
More recent studies suggest polycythemia is less of an 
issue in modern COPD populations. Analysis of a prospective 
cohort of 683 stable COPD outpatients by Cote et al revealed 
a prevalence of only 6%,66 while only 8.4% of over 2500 
French patients with severe COPD receiving LTOT had a 
hematocrit greater than 55%.67 This low prevalence may be 
at least partially attributable to the widespread prescription 
of LTOT in severe COPD populations.
Strikingly, anemia seems highly prevalent in these 
populations, and is predictive of increased mortality. Indeed, 
Chambellan et al found mortality decreased by 14% for every 
5% increase in hematocrit.67 A number of explanations have 
been advanced to account for these findings. COPD is associ-
ated with chronic, low-grade systemic inflammation, which 
may lead to anemia of chronic disease,68 and emerging evi-
dence suggests clinically occult chronic kidney disease may 
be common in elderly patients with COPD, potentially lead-
ing to anemia via impaired production of erythropoietin.69
The development of polycythemia in response to hypox-
emia is critically dependent on the transcription factor 
hypoxia-inducible factor (HIF)-1, which functions as the 
master regulator of cellular oxygen homeostasis. HIF-1 is a 
heterodimeric protein consisting of a constitutively expressed 
β subunit, and an oxygen-regulated α subunit. In normoxic 
conditions, the latter is hydroxylated by a family of proline 
hydroxylases, and subsequently ubiquinated and degraded. 
The presence of cellular hypoxia allows stable HIF-1 to 
induce adaptive genes, such as vascular endothelial growth 
factor and erythropoietin.70 However, HIF-1 can lead to mal-
adaptive responses. One example of this is the generation of 
polycythemia in patients with COPD, resulting from HIF-1 
upregulation driven by hypoxemia.
A number of interventions have been assessed in poly-
cythemic COPD patients. In the Nocturnal Oxygen Therapy 
Trial, continuous oxygen therapy had a greater beneficial impact 
on mortality in patients with a hematocrit of .47.4%,54 while 
the Medical Research Council study showed LTOT reduced risk 
of death in patients with hypoxic cor pulmonale, hypercapnia, 
and secondary polycythemia.55 Pharmacological interventions, 
such as administration of theophylline71 or antagonism of the 
  renin-angiotensin pathway with losartan, may reduce   secondary 
erythrocytosis in COPD patients.72 In selected subjects, 
  venesection can ameliorate pulmonary hypertension.73
While relatively uncommon in modern COPD popu-
lations, historic evidence suggests that, when present, 
polycythemia can contribute to diminished quality of life, 
increased morbidity, and excess mortality. As with pulmo-
nary hypertension, its presence in a COPD patient should 
prompt consideration of supplemental oxygen therapy.
Systemic inflammation
In common with other chronic diseases, subjects with COPD 
have increased circulating markers of systemic inflammation 
when compared with healthy controls.74 Systemic inflam-
mation drives atherosclerosis and promotes cardiovascular 
disease, and in COPD patients may also contribute to the 
development of skeletal muscle dysfunction, osteopenia, 
and depression.75 Moreover, the degree of systemic inflam-
mation present appears to correlate with clinical outcomes. 
Elevated C-reactive protein levels are predictive of increased 
cardiovascular morbidity,76 increased risk of hospitalization, 
and, ultimately, increased mortality.77
Several factors likely play a role in the genesis of systemic 
inflammation of COPD. These include tobacco use, airway 
inflammation, airflow obstruction, and hyperinflation.75 
  However, an independent role for tissue hypoxia seems 
likely.
The transcription factor nuclear factor κB (NFκB) is the 
master regulator of cellular inflammatory responses, control-
ling expression of key inflammatory cytokines, such as tumor 
necrosis factor alpha (TNFα) and interleukin-8.78 Evidence 
of a role for hypoxia in the induction of an NFκB response 
comes from in vitro, in vivo, and clinical studies. Intermittent 
hypoxia is classically seen in patients with obstructive sleep 
apnea syndrome, but may arise in COPD, particularly during 
sleep or exertion. Intermittent hypoxia induces upregulation 
of NFκB- dependent cytokines in endothelial cells in vitro, 
while systemic inflammation increases with nocturnal hypox-
emia in subjects with obstructive sleep apnea syndrome.79
In sustained hypoxia, NFκB appears to interact with 
HIF-1α to promote the expression of inflammatory genes, 
such as cyclo-oygenase II.80 Similarly, in a rodent model, 
24 hours of sustained hypoxia has been shown to upregu-
late NFκB activity in pulmonary and cardiac tissue.80 International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Meanwhile, clinical studies in COPD patients have found 
that circulating levels of TNFα and soluble TNF receptors 
increase as arterial oxygen tension decreases.81
How systemic inflammation arises in COPD remains 
somewhat controversial.
A number of studies have suggested it may result from 
“overspill” of inflammatory mediators from the lungs and 
pulmonary circulation, while others have failed to find any 
correlation between measurable pulmonary and circulating 
inflammatory mediators.82
One potentially important source of inflammation in 
obese patients with COPD is white adipose tissue. In obese 
subjects, white adipose tissue is dysfunctional and inflamed. 
A growing body of evidence supports a role for tissue hypoxia 
in the genesis of this inflammation.83 Indeed, adipose tissue 
oxygenation appears to correlate negatively with the degree 
of obesity present.84 When exposed to hypoxia in vitro, 
adipocytes take on a dysfunctional, diabetogenic, and 
proinflammatory phenotype.83 Obesity is highly prevalent 
in modern COPD cohorts, and recent studies would suggest 
white adipose tissue inflammation is significantly greater in 
hypoxemic patients with advanced disease.85
This systemic inflammation is at least partially   reversible. 
Treatment with inhaled or oral corticosteroids has been 
shown to reduce the degree of systemic inflammation in 
COPD patients.86 However, trials of more targeted anti-
inflammatory therapies have been disappointing. Blockade of 
TNFα with the monoclonal antibody, infliximab, in patients 
with moderate-severe COPD fails to produce a significant 
decrease in systemic inflammation, provides no objective 
clinical benefit, and may be associated with an increased risk 
of pneumonia.87,88 The effect of supplemental oxygen therapy 
in this regard is uncertain, with some authors reporting an 
increase, and others a decrease, of inflammatory markers 
following oxygen administration.89,90
Skeletal muscle dysfunction
Skeletal muscle dysfunction is an important extrapulmonary 
consequence of COPD. Particularly affecting the quadriceps, 
this manifests as decreased muscle strength with reduced 
endurance capacity. At a microscopic level, muscle fiber atro-
phy and alteration of fiber type can be seen.91 The presence 
of skeletal muscle dysfunction is a key prognostic indicator 
in patients with severe COPD. Muscle weakness is predictive 
of reduced exercise capacity, increased health care utilization, 
and increased risk of readmission following hospitalization 
for an exacerbation.92 In patients with   moderate-severe 
disease, reduced quadriceps strength predicts increased 
mortality, independent of age, nutritional status, or degree 
of airflow obstruction.93
A number of factors appear to interact in the generation of 
skeletal muscle dysfunction in COPD. These include disuse 
atrophy, malnutrition, corticosteroid usage, and hormonal 
dysregulation.91 However, there is increasing evidence 
that chronic hypoxemia may significantly contribute to 
this   process. Healthy subjects exposed to chronic hypoxia 
at   altitude undergo a reduction in muscle strength and 
endurance, with a concomitant alteration in composition.94 
Similarly, chronically hypoxemic COPD patients have 
accentuated muscle dysfunction, an effect that is partially 
reversed by supplemental oxygen.95
Hypoxia may contribute to skeletal muscle dysfunction 
in COPD patients by a number of mechanisms. As discussed 
above, hypoxia helps generate the low-grade chronic sys-
temic inflammation that characterizes COPD. TNFα can 
provoke muscle cell apoptosis and protein degradation via the 
ubiquitin/proteasome system.91 Levels of TNFα, and of other 
circulating inflammatory cytokines, such as interleukin-8, 
have been shown to correlate with the degree of muscle 
dysfunction in COPD,96 while NFκB activation appears 
to occur in the skeletal muscle of COPD patients with low 
body weight.97 These findings have suggested that systemic 
inflammation may be a contributory factor in skeletal muscle 
dysfunction. However, other studies have failed to demon-
strate an increase in inflammatory cytokine expression in 
quadriceps biopsies from patients with severe COPD,98 and 
the area remains somewhat controversial.
Another possible contributor to skeletal muscle dysfunc-
tion is the generation of oxidative stress. Reactive oxygen 
species are produced in normal aerobic metabolism, and at 
physiological levels act in a beneficial manner, participat-
ing in cell signaling and host-defense against infection. 
However, higher concentrations of reactive oxygen species 
can mediate damage to lipids, proteins, and DNA, and drive 
inflammatory cascades. Reactive oxygen species generation 
is usually balanced by enzymatic (eg, superoxide dismutase) 
and nonenzymatic (eg, glutathione) antioxidant defense 
mechanisms. Oxidative stress occurs when there is an imbal-
ance between the generation of reactive oxygen species and 
antioxidant capacity. Oxidative stress impairs skeletal muscle 
contractility, and subjects with COPD have evidence of 
increased oxidative stress, particularly following exercise.93,99 
This effect appears particularly marked in chronically 
hypoxemic subjects, in whom markers of oxidative stress International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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are   significantly increased in peripheral muscle specimens 
at rest and following exercise.100
Chronic hypoxemia may also directly affect smooth 
muscle function. The AKt/mTOR (mammalian target of 
rapamycin) pathway regulates skeletal muscle mass and 
prevents muscle atrophy.101 Hypoxia has been demonstrated 
to downregulate this pathway in a rodent model, possibly via 
overexpression of the hypoxia-induced gene, REDD1 (regu-
lated in development and DNA damage response 1), thus 
leading to reduced muscle mass.102 Comparative analysis of 
skeletal muscle from hypoxemic and nonhypoxemic COPD 
patients demonstrates inhibition of mTOR signaling in the 
former. Furthermore, von Hippel-Lindau protein appears 
to be overexpressed in the skeletal muscle of patients with 
COPD, thereby potentially impairing HIF-1α-mediated 
adaptive pathways in hypoxia.103
Thus, chronic hypoxemia may contribute to skeletal 
muscle dysfunction via both systemic factors, such as 
systemic inflammation, and local factors, such as direct 
inhibition of cellular pathways and local induction of 
oxidative stress.
Neurocognitive dysfunction
Neurocognitive dysfunction appears to be relatively common 
in COPD populations, and appears to increase in prevalence 
with impairment in gas exchange.104 When present, impaired 
cognitive function is associated with reduced quality in life, 
and may be predictive of increased morbidity and mortality 
in COPD patients. A number of factors have been postulated 
to contribute to this, including concomitant vascular disease 
and smoking. However, resting hypoxemia appears to be a 
key risk factor, with markedly increased prevalence among 
subjects with severe hypoxemia.104 Suggested mechanisms 
include systemic inflammation and oxidative stress leading 
to direct neuronal damage, as well as depletion of neurotrans-
mitters due to dysfunction of oxygen-dependent enzymes. 
Once again, the potential benefits of oxygen therapy are 
debated, with some authors failing to demonstrate any 
effect,105 while others have found supplemental oxygen to be 
protective against, or capable of ameliorating, neurocognitive 
dysfunction.106,107
Supplemental oxygen therapy
Although supplemental oxygen had been used in the treat-
ment of patients with emphysema and chronic bronchitis 
for decades, its ability to prolong survival in selected 
COPD populations was only conclusively established in 
the early 1980s. The Nocturnal Oxygen Therapy Trial 
and Medical Research Council trial, both relatively small 
by modern standards, demonstrated increased survival in 
markedly hypoxemic patients receiving more than 18 hours 
of supplemental oxygen per day when compared either 
with those receiving oxygen for 12 hours per day, or those 
receiving no treatment.54,55 Subsequent studies have shown 
supplemental oxygen can reduce pulmonary hypertension, 
improve neurocognitive function, increase exercise tolerance, 
and reduce frequency of exacerbations.5
Its utility in populations with moderate daytime hypox-
emia, nocturnal hypoxemia, or exertional oxyhemoglobin 
desaturation remains less clear. The available evidence sug-
gests that supplemental oxygen does not prolong survival 
in these patients, but further carefully designed studies 
investigating its potential to improve survival, function, and 
well-being are warranted.108
The use of supplemental oxygen is not free of risk. 
When administered in supraphysiological doses, oxygen 
therapy can lead to diminished ventilatory drive, increased 
ventilation/perfusion mismatch, and consequent hypercapnia. 
However, controlled oxygen therapy, targeting an oxygen 
saturation in the 90%–92% range, is not likely to result in 
clinically significant hypercapnia.109 Oxygen administra-
tion has been shown to generate oxidative stress and airway 
inflammation, which could theoretically contribute to further 
tissue damage and progression of disease.5
Finally, the drawbacks of LTOT use are not all medical. 
Quite apart from significant financial cost, and the perceived 
societal stigma of LTOT, the combination of cigarette smok-
ing and oxygen use is a potentially lethal one. Although this 
is generally considered to be an absolute contraindication 
to the prescription of supplemental oxygen, reports suggest 
up to 20% of COPD patients receiving LTOT may be active 
smokers.110 Whether supplemental oxygen therapy should be 
withdrawn from such patients remains an underexplored and 
a rather fraught question.
Conclusion
Alveolar hypoxia and consequent hypoxemia increase in 
prevalence as COPD severity increases. Chronic hypox-
emia contributes to the development of adverse sequelae 
of COPD, such as pulmonary hypertension, secondary 
polycythemia, skeletal muscle dysfunction, and systemic 
inflammation. These comorbidities reduce quality of life 
in COPD patients, and predispose them to acute exacerba-
tions, cardiovascular morbidity, and increased risk of death. International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Supplemental oxygen therapy improves quality of life and 
survival in selected cases. However, its role in patients 
with moderate hypoxia, or isolated exertional or nocturnal 
hypoxia, remains unclear.
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